InSilico Medicine Cayman TopCo (英矽智能) (Stock Code: 3696) announced the full exercise of the Over-allotment Option described in its Prospectus on January 16, 2026. A total of 14,203,500 shares—representing approximately 15% of the initial offer size—will be issued at HK$24.05 per share. The newly issued shares will cover the over-allocations under the International Offering and facilitate the return of borrowed shares to the lender.
According to the announcement, approval for the listing and dealing of these Over-allotment Shares on the Main Board of the Hong Kong Stock Exchange has already been granted. Listing of and dealings in these shares are expected to commence at 9:00 a.m. on January 21, 2026.
Upon completion of the Over-allotment Option, total shares in issue will increase from 557,418,500 shares to 571,622,000 shares. The proportion of shares issued through the Global Offering will rise from 16.99% to 19.05% of the Company's total issued share capital. In the process, InSilico Medicine Cayman TopCo is expected to receive approximately HK$324.5 million in additional net proceeds, which will be allocated in the same categories and proportions as originally stated in the “Future Plans and Use of Proceeds” section of the Prospectus.
The Company stated it will continue to meet the required public float thresholds under Hong Kong listing rules once the Over-allotment Option exercise is completed. A further announcement will be made following the end of the stabilization period as required by applicable regulations.
Comments